COMMON STOCK PURCHASE WARRANT CNS Pharmaceuticals Inc.CNS Pharmaceuticals, Inc. • June 15th, 2018 • Pharmaceutical preparations • Texas
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the “Initial Exercise Date” (which is the Issue Date) and on or prior to the close of business on the fifth (5th) anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from CNS Pharmaceuticals Inc, a Delaware corporation (the “Company”), up to ________________ shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
EMPLOYMENT AGREEMENTEmployment Agreement • June 15th, 2018 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of September 1, 2017 (the “Effective Date”), by and between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”) having its principal place of business at PO Box 79897, Houston, TX 77279, and John Climaco (“Executive”, and the Company and the Executive collectively referred to herein as the “Parties”) having his office at PO Box 326, Park City, Utah 84060, or such other location of his choosing.
THIS INSTRUMENT HAS BEEN ISSUED PURSUANT TO SECTION 4(A)(6) OF THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND NEITHER IT NOR ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES...CNS Pharmaceuticals, Inc. • June 15th, 2018 • Pharmaceutical preparations • Texas
THIS CERTIFIES THAT in exchange for the payment by [Investor Name] (the “Investor”) of $____________ (the “Purchase Amount”) on or about [Date of Crowd Safe], CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby issues to the Investor the right to certain shares of the Company’s capital stock, subject to the terms set forth below.
CONSULTING AGREEMENTConsulting Agreement • June 15th, 2018 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations
This Consulting Agreement is effective as of July 27, 2017, by and between CNS Pharmaceuticals Inc., a Nevada corporation (the “Company”), with offices located at PO Box 79897, Houston, TX 77498, and Fresh Notion Financial Services (the “Consultant”), at PO Box 79897, Houston, TX 77498.
ContractAmended And • June 15th, 2018 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This AMENDED AND RESTATED PATENT LICENSE AGREEMENT (the “Agreement”) effective as of December 28, 2017 (the “Effective Date”) is entered into by and between CNS Pharmaceuticals, Inc. (“CNS”), a Nevada corporation, having a business address of 2575 West Bellfort, Suite 225 Houston, TX 77054 and Houston Pharmaceuticals, Inc., (“HPI”), a Texas Corporation, having a business address of 4239 Emory St., Houston, TX 77005. CNS and HPI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Collaboration and Asset Purchase Agreement Between Reata Pharmaceuticals, Inc. and CNS Pharmaceuticals, Inc.Collaboration and Asset Purchase Agreement • June 15th, 2018 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Collaboration and Asset Purchase Agreement (the “Agreement”) is made and entered into as of November 21, 2017 (the “Effective Date”), by and between Reata Pharmaceuticals, Inc., a Delaware corporation (“Reata”), having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, TX 75063 and CNS Pharmaceuticals, Inc. (“CNS”), a Nevada corporation having its principal place of business at 14405 Walters Road, Suite 781, Houston, TX 77014. Reata and CNS are each referred to herein as a “Party” and collectively as the “Parties.”
